Three Combinations Of Docetaxel And Irinotecan For Recurrent Or Metastatic Non Small Cell Lung Cancer

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2003
A multicenter randomized phase II study evaluating the activity and tolerability of three different combinations of docetaxel (taxotere) and irinotecan (campto) as second line therapy for recurrent or metastatic non small cell lung cancer (NSCLC)
Epistemonikos ID: 8aea1cf0d574611d2cf11638abe965ec2273a520
First added on: May 04, 2024